Barclays PLC Veracyte, Inc. Transaction History

Barclays PLC

$353 Billion
Q1 2025

A detailed history of Barclays PLC transactions in Veracyte, Inc. stock. As of the latest transaction made, Barclays PLC holds 138,372 shares of VCYT stock, worth $3.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

138,372

Previous 155,338 10.92%

Holding current value

$3.73 Million

Previous $6.15 Million 33.3%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$29.65 - $46.14 $503,041 - $782,811	-16,966 Reduced 10.92%	138,372 $4.1 Million
Q4 2024 Feb 13, 2025	BUY	$31.92 - $44.4 $285,237 - $396,758	8,936 Added 6.1%	155,338 $6.15 Million
Q3 2024 Nov 15, 2024	BUY	$21.0 - $35.25 $1.79 Million - $3 Million	85,033 Added 138.56%	146,402 $4.98 Million
Q2 2024 Aug 14, 2024	SELL	$18.86 - $23.55 $522,591 - $652,546	-27,709 Reduced 31.11%	61,369 $1.33 Million
Q1 2024 May 15, 2024	SELL	$21.0 - $29.1 $1.83 Million - $2.54 Million	-87,312 Reduced 49.5%	89,078 $1.98 Million
Q4 2023 Feb 15, 2024	BUY	$19.72 - $28.68 $855,433 - $1.24 Million	43,379 Added 32.61%	176,390 $4.85 Million
Q3 2023 Nov 07, 2023	SELL	$22.33 - $29.92 $987,186 - $1.32 Million	-44,209 Reduced 24.95%	133,011 $2.97 Million
Q2 2023 Aug 03, 2023	BUY	$20.96 - $26.99 $660,596 - $850,643	31,517 Added 21.63%	177,220 $4.51 Million
Q1 2023 May 04, 2023	SELL	$20.58 - $27.89 $615,259 - $833,799	-29,896 Reduced 17.03%	145,703 $3.25 Million
Q4 2022 Feb 13, 2023	SELL	$15.31 - $29.94 $781,437 - $1.53 Million	-51,041 Reduced 22.52%	175,599 $4.17 Million
Q3 2022 Nov 03, 2022	BUY	$16.58 - $27.9 $3.3 Million - $5.55 Million	198,779 Added 713.47%	226,640 $3.76 Million
Q2 2022 Aug 12, 2022	SELL	$15.45 - $29.52 $86,983 - $166,197	-5,630 Reduced 16.81%	27,861 $555,000
Q1 2022 May 16, 2022	SELL	$21.94 - $42.51 $1.33 Million - $2.58 Million	-60,625 Reduced 64.42%	33,491 $924,000
Q4 2021 Feb 14, 2022	SELL	$36.09 - $53.79 $2.51 Million - $3.73 Million	-69,435 Reduced 42.45%	94,116 $3.88 Million
Q3 2021 Nov 09, 2021	BUY	$35.62 - $52.97 $4.99 Million - $7.43 Million	140,186 Added 599.98%	163,551 $7.6 Million
Q2 2021 Aug 13, 2021	SELL	$32.94 - $56.62 $1.37 Million - $2.35 Million	-41,447 Reduced 63.95%	23,365 $934,000
Q1 2021 May 13, 2021	SELL	$44.47 - $81.38 $1.72 Million - $3.15 Million	-38,678 Reduced 37.37%	64,812 $3.48 Million
Q4 2020 Feb 11, 2021	SELL	$32.49 - $61.88 $378,443 - $720,778	-11,648 Reduced 10.12%	103,490 $5.07 Million
Q3 2020 Nov 12, 2020	BUY	$26.73 - $35.67 $1.44 Million - $1.92 Million	53,953 Added 88.18%	115,138 $3.74 Million
Q2 2020 Aug 12, 2020	BUY	$19.49 - $28.11 $230,293 - $332,147	11,816 Added 23.93%	61,185 $1.59 Million
Q1 2020 May 13, 2020	SELL	$16.13 - $30.17 $13,113 - $24,528	-813 Reduced 1.62%	49,369 $1.2 Million
Q4 2019 Feb 10, 2020	BUY	$20.78 - $29.99 $345,987 - $499,333	16,650 Added 49.65%	50,182 $1.4 Million
Q3 2019 Nov 14, 2019	SELL	$23.87 - $30.93 $378,387 - $490,302	-15,852 Reduced 32.1%	33,532 $805,000
Q2 2019 Aug 14, 2019	BUY	$22.1 - $28.56 $634,004 - $819,329	28,688 Added 138.62%	49,384 $1.41 Million
Q1 2019 May 15, 2019	BUY	$12.0 - $25.76 $94,008 - $201,803	7,834 Added 60.91%	20,696 $518,000
Q4 2018 Feb 14, 2019	SELL	$9.15 - $14.85 $118,748 - $192,723	-12,978 Reduced 50.22%	12,862 $162,000
Q3 2018 Nov 14, 2018	BUY	$9.55 - $12.64 $221,197 - $292,767	23,162 Added 864.9%	25,840 $247,000
Q2 2018 Aug 14, 2018	SELL	$5.39 - $9.66 $14,434 - $25,869	-2,678 Reduced 50.0%	2,678 $24,000
Q1 2018 May 15, 2018	BUY	$5.44 - $6.97 $8,693 - $11,138	1,598 Added 42.52%	5,356 $29,000
Q4 2017 Feb 14, 2018	BUY	$6.05 - $9.37 $18,422 - $28,531	3,045 Added 427.07%	3,758 $25,000
Q3 2017 Nov 14, 2017	BUY	$7.81 - $8.77 $5,568 - $6,253	713	713 $6,000

Others Institutions Holding VCYT

# of Institutions

306

Shares Held

79.1M

Call Options Held

15.5K

Put Options Held

16.7K

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $1.93B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account